Live feed08:30:00·46dPRReleasevia QuantisnowPolaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)ByQuantisnow·Wall Street's wire, on your screen.PLYX· Polaryx Therapeutics Inc.Health Care
